Long-term efficacy of CMV/EBV bivirus-specific T cells for viral co-reactivation after stem cell transplantationOACSCDCSTPCD
Long-term efficacy of CMV/EBV bivirus-specific T cells for viral co-reactivation after stem cell transplantation
Xuying Pei;Xiaohui Zhang;Xiaojun Huang;Xiangyu Zhao;Meng Lv;Xiaodong Mo;Yuqian Sun;Yuhong Chen;Chenhua Yan;Yuanyuan Zhang;Lanping Xu;Yu Wang
Peking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China||Peking-Tsinghua Center for Life Sciences,Beijing 100091,China||State Key Laboratory of Natural and Biomimetic Drugs,Beijing 100083,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China
《中华医学杂志（英文版）》 2025 (5)
607-609,3
This work was funded by the National Key Research and Development Program of China(No.2022YFA0103300),Being Nova Program(No.20220484076),Major Program of the National Natural Science Foundation of China(Nos.82070184 and 82293630),Beijing Municipal Science &Technology Commission(No.Z211100002921071),and Peking University Clinical Scientist Training Program(No.BMU2024PYJH012).
评论